Skip to main content

Table 4 Progression-free survival/multivariate analysis/

From: Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy

Factor Variant Cases n (%) HR (±95% CI) P
Histotype Non-serous 57 (44.2) 1 (ref)  
Serous 72 (55.8) 5.04 (2.05-12.37) 0.0004
FIGO 1 + 2 58 (46.0) 1 (ref)  
3 + 4 68 (54.0) 2.19 (1.03-4.64) 0.041
ABCB1 p.Ser893Ala p.Ser893Thr rs2032582 Common allele carriers (GG + GT + GA) 101 (80.2) 1 (ref)  
Rare genotypes (AT + TT) 25 (19.8) 2.14 (1.07-4.28) 0.031
ATM p.Asp1853Asn rs1801516 Rare allele carriers (GA + AA) 87 (61.0) 1 (ref)  
Common homozygote (GG) 39 (39.0) 2.32 (1.06-5.10) 0.036
  1. Statistically significant analyses are in bold.